Search for:
Search for:
Healthcare Professionals
Publications
News
Español
Contact
Magazine
Radio
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Donate
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Outreach
Awareness Campaigns
Host an Event
Events
Test Flyout
lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem...
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
News & Features
Town Hall
Join us at 4:30 p.m. Eastern, 3:30 p.m. Central, 2:30 p.m. Mountain, 1:30 p.m. Pacific, on Aug. 9, for
Town...
/Events/MSF-Events/2022/August/Town-Hall
Assistive Technology P...
The Assistive Technology Program provides information about, and funding for, devices that help...
/Get-Help/MSF-Programs-Grants/Assistive-Technology-Program
Shop
Privacy
Terms of Use
Site Map
Anti-inflammatory therapy slows MS progression in mice
October 30, 2020
A new study suggests intranasal administration of an anti-inflammatory drug helped reduce disease progression in a preclinical model of multiple sclerosis. Researchers showed delivering an anti-inflammatory drug to mice helped prevent damage to brain cells, effectively slowing the progression of the disease.
Researchers at the University of Alberta identified a drug called VX-765 as a strong candidate therapy for MS patients. The drug works by inhibiting caspase-1, a component of inflammasomes that promotes harmful inflammation in the body. In previous research, the study’s authors saw beneficial results by delivering insulin intranasally in other models of brain inflammation, and they decided to go with that delivery route again.
Using mouse models, researchers dissolved VX-765 in a fluid and then injected the mixture into the nose. To examine the effect of VX-765 on the nerves, researchers used positron emission tomography scans to look at brain metabolism and were able to document whether the insulation had been stripped or not after the therapy was delivered. The study shows intranasal therapy is effective in preventing demyelination and axon injury and loss.
Results of mouse model studies sometimes do not translate to humans and may be years away from being a marketable treatment. However, researchers said the loss of myelin and loss of nerves are irreversible processes, so any therapeutic that helps to slow or prevent that from happening is an exciting advance for MS research. The particular delivery method also allows the therapy to be delivered in a more precise and targeted way.
The study was published in the journal
GLIA
.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more